Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
David John Sutton
Observed names:
David J Sutton,
David J. Sutton,
Sutton, D
Institution:
University Hospitals of North Midlands NHS Trust
Observed institutions:
Mid Cheshire Hospitals NHS Foundation Trust,
Heart of England NHS Foundation Trust,
University Hospitals of North Midlands NHS Trust,
Royal Stoke University Hospital,
University of Birmingham
ORCID:
0000-0001-5279-6889
Observed ORCID:
0000-0001-5279-6889
OpenAlex ID:
A5076153576
A UK-wide analysis of 2265 patients receiving a reversal agent for direct oral anticoagulant–associated bleeding
2025
·
Richard J. Buka
, Michala Pettitt
, et al.
·
Journal of Thrombosis and Haemostasis
·
10
PDF
How will UK hospitals use andexanet alfa? A review of local protocols
2023
·
Paula Glancy
, David J. Sutton
, et al.
·
eJHaem
·
9
PDF
Cancer is not a single disease: is it safe to extrapolate evidence from trials of direct oral anticoagulants in cancer‐associated venous thromboembolism to patients with haematological malignancies?
2021
·
Richard J. Buka
, Deepak Chandra
, et al.
·
British Journal of Haematology
·
5
PDF
Rapido: Results from a UK-Wide Audit of 2477 Patients Who Received a Reversal Agent for a Direct Oral Anticoagulant
2024
·
Richard John Buka
, Pettitt E Michala
, et al.
·
Blood
·
3
PDF
DOACs for VTE in patients with brain cancer and brain metastases: choices, choices, choices
2022
·
Richard J. Buka
, David J. Sutton
·
Blood Advances
·
3
PDF
Fatal drug reaction to andexanet alfa: a case report
2024
·
Richard J. Buka
, Mamidipudi T. Krishna
, et al.
·
eJHaem
·
2
A UK-wide analysis of the use of reversal agents in 198 patients on direct oral anticoagulants prior to urgent procedures
2026
·
Molly Murphy
, Michala Pettitt
, et al.
·
Research and Practice in Thrombosis and Haemostasis
·
1
Use of andexanet alfa: A British Society for Haematology position statement
2026
·
Richard J. Buka
, Deepa J. Arachchillage
, et al.
·
British Journal of Haematology
Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
2024
·
Richard J Buka
, David J Sutton
, et al.
·
Journal of Thrombosis and Thrombolysis
12-Month Full Donor Chimerism Is Associated with Low-Grade Acute Graft Versus Host Disease (aGVHD) and Predicts Superior Outcomes in Reduced Intensity (RIC) Alemtuzumab-Based Transplants for MDS and AML
2016
·
Alex George Kanellopoulos
, Shankaranarayana Paneesha
, et al.
·
Blood
Efficacy and Safety of Melphalan 140mg/m2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma
2016
·
Hatem Ali
, Baharani Jyoti
, et al.
·
Blood
A study of autologous stem cell transplantation in young patients with multiple myeloma.
2002
·
Wechalekar, AD
, Reece, D
, et al.
·
UCL Discovery (University College London)
Show more works
View as search
Works count:
12
Citation count:
33
H-index:
3
I10-index:
1
Year
Topic
Type